Dr. Sunil Desai, M.B.Ch.B., FRCP(c)
Claim this profileStollery Children's Hospital
Studies Lymphoma
Studies Lymphoblastic Leukemia-Lymphoma
3 reported clinical trials
4 drugs studied
Area of expertise
1Lymphoma
NTRK positive
Stage IV
ALK positive
2Lymphoblastic Leukemia-Lymphoma
CD19 positive
Affiliated Hospitals
Clinical Trials Sunil Desai, M.B.Ch.B., FRCP(c) is currently running
Repotrectinib
for Solid Tumors in Young Patients
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). Phase 2 will determine the anti-tumor activity of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring ROS1 or NTRK1-3 alterations.
Recruiting1 award Phase 1 & 214 criteria
CAR T-cell Therapy
for Acute Lymphoblastic Leukemia
This trial involves using a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The target group is patients with certain types of cancers. The modified cells are reintroduced into the patient to help their immune system fight the cancer more effectively. This approach has shown promising results in treating these cancers.
Recruiting1 award Phase 1 & 212 criteria
More about Sunil Desai, M.B.Ch.B., FRCP(c)
Clinical Trial Related8 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Sunil Desai, M.B.Ch.B., FRCP(c) has experience with
- Repotrectinib
- Vorinostat
- Bortezomib
- Autologous CD19-directed Chimeric Antigen Receptor (CAR) T-cells
Breakdown of trials Sunil Desai, M.B.Ch.B., FRCP(c) has run
Lymphoma
Lymphoblastic Leukemia-Lymphoma
Lymphoid Leukemia
Acute Lymphoblastic Leukemia
Central Nervous System Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sunil Desai, M.B.Ch.B., FRCP(c) specialize in?
Sunil Desai, M.B.Ch.B., FRCP(c) focuses on Lymphoma and Lymphoblastic Leukemia-Lymphoma. In particular, much of their work with Lymphoma has involved NTRK positive patients, or patients who are Stage IV.
Is Sunil Desai, M.B.Ch.B., FRCP(c) currently recruiting for clinical trials?
Yes, Sunil Desai, M.B.Ch.B., FRCP(c) is currently recruiting for 2 clinical trials in Edmonton Alberta. If you're interested in participating, you should apply.
Are there any treatments that Sunil Desai, M.B.Ch.B., FRCP(c) has studied deeply?
Yes, Sunil Desai, M.B.Ch.B., FRCP(c) has studied treatments such as Repotrectinib, Vorinostat, Bortezomib.
What is the best way to schedule an appointment with Sunil Desai, M.B.Ch.B., FRCP(c)?
Apply for one of the trials that Sunil Desai, M.B.Ch.B., FRCP(c) is conducting.
What is the office address of Sunil Desai, M.B.Ch.B., FRCP(c)?
The office of Sunil Desai, M.B.Ch.B., FRCP(c) is located at: Stollery Children's Hospital, Edmonton, Alberta T6G 2B7 Canada. This is the address for their practice at the Stollery Children's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.